World Journal of Surgery

, Volume 38, Issue 11, pp 2986–2993 | Cite as

S-1 vs. Gemcitabine as an Adjuvant Therapy after Surgical Resection for Ductal Adenocarcinoma of the Pancreas

  • Takehiro Okabayashi
  • Yasuo Shima
  • Jun Iwata
  • Sojiro Morita
  • Tatsuaki Sumiyoshi
  • Akihito Kozuki
  • Teppei Tokumaru
  • Tatsuo Iiyama
  • Takuhiro Kosaki
  • Michiya Kobayashi
  • Kazuhiro Hanazaki
Original Scientific Report

Abstract

Background

Pancreatectomy with regional lymphadenectomy remains the only curative treatment option for pancreatic cancer. There is no clear consensus on what type of adjuvant therapy should be used for patients with pancreatic cancer.

Objective

Our objective was to retrospectively evaluate whether postoperative adjuvant chemotherapy using S-1 is clinically beneficial in managing resectable pancreatic cancer.

Methods

Patients were divided into three groups: those undergoing surgery alone, those receiving gemcitabine infusion, and those receiving S-1 orally.

Results

Of 189 studied patients, the median overall survival was 15.0 months after surgery alone, 33.0 months in the gemcitabine group, and 45.0 months in patients receiving S-1. A multivariate analysis identified regional lymph node metastasis, positive surgical margins, and absence of adjuvant chemotherapy as independent negative prognostic factors. S-1 was not inferior to gemcitabine in terms of survival outcomes and showed a favorable hazard ratio compared with gemcitabine in the subsets of patients with positive vascular invasion.

Conclusions

There was no difference between adjuvant chemotherapy with S-1 and gemcitabine in overall survival for patients with curative pancreatic cancer. Our results suggested that S-1 can be used as a second agent to gemcitabine after surgical resection for ordinary adenocarcinoma of the pancreas.

Notes

Acknowledgment

This work was supported by the Kochi Organization for Medical Reformation and Renewal Grants.

Conflict of interest

The authors state that there are no conflicts of interest or financial disclosures.

References

  1. 1.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMedCrossRefGoogle Scholar
  2. 2.
    Neoptolemos JP, Stocken DD, Friess H et al (2004) European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210PubMedCrossRefGoogle Scholar
  3. 3.
    Choti MA (2004) Adjuvant therapy for pancreatic cancer–the debate continues. N Engl J Med 350:1249–1251PubMedCrossRefGoogle Scholar
  4. 4.
    Michalski CW, Kleeff J, Wente MN et al (2007) Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 94:265–273PubMedCrossRefGoogle Scholar
  5. 5.
    Konstantinidis IT, Warshaw AL, Allen JN et al (2013) Pancreatic ductal adenocarcinoma: is there a survival difference for r1 resections versus locally advanced unresectable tumors? what is a “true” r0 resection? Ann Surg 257:731–736PubMedCrossRefGoogle Scholar
  6. 6.
    Mollberg N, Rahbari NN, Koch M et al (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 254:882–893PubMedCrossRefGoogle Scholar
  7. 7.
    Jemal A, Siegel R, Ward E et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  8. 8.
    Birkmeyer JD, Stukel TA, Siewers AE et al (2003) Surgeon volume and operative mortality in the United States. N Engl J Med 349:2117–2127PubMedCrossRefGoogle Scholar
  9. 9.
    Yeo CJ, Cameron JL, Lillemoe KD et al (2002) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236:355–366PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Neoptolemos JP, Stocken DD, Bassi C et al (2010) European study group for pancreatic cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081PubMedCrossRefGoogle Scholar
  11. 11.
    Regine WF, Winter KA, Abrams RA et al (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299:1019–1026PubMedCrossRefGoogle Scholar
  12. 12.
    Berger AC, Garcia M Jr, Hoffman JP et al (2008) Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26:5918–5922PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Conroy T, Desseigne F, Ychou M et al (2011) Groupe tumeurs digestives of unicancer; prodige intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825PubMedCrossRefGoogle Scholar
  14. 14.
    Ueno H, Okusaka T, Ikeda M et al (2005) A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 69:421–427PubMedCrossRefGoogle Scholar
  15. 15.
    Okusaka T, Funakoshi A, Furuse J et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615–621PubMedCrossRefGoogle Scholar
  16. 16.
    Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648PubMedCrossRefGoogle Scholar
  17. 17.
    Cascinu S, Jelic S (2009) ESMO guidelines. Working group pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):37–40PubMedGoogle Scholar
  18. 18.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457CrossRefGoogle Scholar
  19. 19.
    Cox DR (1972) Regression models and life tables. J R Stat Soc 187:34BGoogle Scholar
  20. 20.
    Uesaka K, Fukutomi A, Boku N et al (2012) Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30 (Suppl 34; abstract 145)Google Scholar
  21. 21.
    Chaulagain CP, Ng J, Goodman MD et al (2013) Adjuvant therapy of pancreatic cancer. JOP 14:119–122PubMedGoogle Scholar
  22. 22.
    Haller DG, Cassidy J, Clarke SJ et al (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26:2118–2123PubMedCrossRefGoogle Scholar
  23. 23.
    Chuah B, Goh BC, Lee SC et al (2011) Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 102:478–483PubMedCrossRefGoogle Scholar
  24. 24.
    Murakami Y, Uemura K, Sudo T et al (2013) Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol 71(2):419–429PubMedCrossRefGoogle Scholar
  25. 25.
    Murakami Y, Uemura K, Sudo T et al (2012) Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. J Surg Oncol 106:174–180PubMedCrossRefGoogle Scholar
  26. 26.
    Neoptolemos JP, Cunningham D, Friess H et al (2003) Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 14:675–692PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2014

Authors and Affiliations

  • Takehiro Okabayashi
    • 1
  • Yasuo Shima
    • 1
  • Jun Iwata
    • 2
  • Sojiro Morita
    • 3
  • Tatsuaki Sumiyoshi
    • 1
  • Akihito Kozuki
    • 1
  • Teppei Tokumaru
    • 1
  • Tatsuo Iiyama
    • 4
  • Takuhiro Kosaki
    • 5
  • Michiya Kobayashi
    • 6
  • Kazuhiro Hanazaki
    • 6
  1. 1.Department of Gastroenterological SurgeryKochi Health Sciences CenterKochi-CityJapan
  2. 2.Department of Diagnostic PathologyKochi Health Sciences CenterKochi-CityJapan
  3. 3.Department of RadiologyKochi Health Sciences CenterKochi-CityJapan
  4. 4.Department of BiostatisticsKochi Medical SchoolKochi-CityJapan
  5. 5.Department of Gastroenterology and HepatologyKochi Medical SchoolKochi-CityJapan
  6. 6.Department of SurgeryKochi Medical SchoolKochi-CityJapan

Personalised recommendations